QMS milestone achieved
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Nexsen Limited has announced the achievement of a significant milestone in its Quality Management System, which is essential for the development and commercialization of its diagnostic products, including StrepSure. This progression is crucial for Nexsen's global regulatory and commercial expansion efforts across various markets, including the United States and Australia. The filing highlights the importance of a certified QMS for regulatory approvals and efficient market access.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Nexsen
- HK$6 million grant awarded to advance Asia-Pacific execution
- Nexsen accelerates global rollout for StrepSure
- FDA feedback derisks US approval pathway for StrepSure
- Half Yearly Report and Accounts
- Quarterly Report - Q2 FY26
Later from Nexsen
- Quarterly Report - Q3 FY26
- Nexsen and Universiti Malaya launch joint facility
- Nexsen secures first hospital partner in Asia
- $1.5m non-dilutive ARC funding for manufacturing
- Quarterly Report - Q4 FY26
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen